We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Biovail Fires Back At AstraZeneca In Seroquel IP Suit

Law360 (April 6, 2009, 12:00 AM EDT) -- Biovail Corp. has become the latest generics maker to ask a court to invalidate or rule unenforceable two patents for Seroquel XR — AstraZeneca Pharmaceuticals LP's popular treatment for bipolar disorder and schizophrenia — filing counterclaims that accuse the pharmaceutical giant of inequitable conduct.

The counterclaims, filed Friday in the U.S. District Court for the District of New Jersey, argue that one of the patents is unenforceable because the patent applicants failed to share pertinent information with the U.S. Patent and Trademark Office and tried to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.